Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: Pharmacodynamic studies - PubMed (original) (raw)
Differential effects of the 18-kDa translocator protein (TSPO) ligand etifoxine on steroidogenesis in rat brain, plasma and steroidogenic glands: Pharmacodynamic studies
Philippe Liere et al. Psychoneuroendocrinology. 2017 Sep.
Abstract
Etifoxine is indicated in humans for treating anxiety. In rodents, besides its anxiolytic-like properties, it has recently shown neuroprotective and neuroregenerative activities. It acts by enhancing GABAA receptor function and by stimulating acute steroid biosynthesis via the activation of the 18-kDa translocator protein. However, the regulatory action of etifoxine on steroid production is not well characterized. In this work, we performed dose-response, acute and chronic time-course experiments on the effects of intraperitoneal injections of etifoxine on steroid levels in adult male rat brain and plasma analyzed by gas chromatography-mass spectrometry. Concentrations of pregnenolone, progesterone and its 5α-reduced metabolites were significantly increased in both tissues in response to 25 and 50mg/kg of etifoxine, as compared with vehicle controls, and reached maximal values at 0.5-1h post-injection. Daily injections of etifoxine (50mg/kg, 15days) kept them increased at day 15. Comparisons between steroidogenic tissues revealed that 1h after 50mg/kg of etifoxine treatment, levels of pregnenolone, progesterone and corticosterone were highest in adrenal glands and markedly increased together with their reduced metabolites. They were also increased by etifoxine in brain and plasma, but not in testis except for corticosterone and its metabolites. In contrast, testosterone level was significantly decreased in testis while with its 5α-reduced metabolites, it was unchanged in brain. Results demonstrate that the modulation of steroid concentrations by etifoxine is dependent on the type of steroid and on the steroidogenic organ. They further suggest that adrenal steroids upregulated by etifoxine make an important contribution to the steroids present in brain. This work provides a precise and complete view of steroids regulated by etifoxine that could be useful in therapeutic research.
Keywords: Endocrine glands; Etifoxine; Gas chromatography-mass spectrometry; Kinetic; Nervous system; Neurosteroids; TSPO.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
- The Anxiolytic Etifoxine Binds to TSPO Ro5-4864 Binding Site with Long Residence Time Showing a High Neurosteroidogenic Activity.
Costa B, Cavallini C, Da Pozzo E, Taliani S, Da Settimo F, Martini C. Costa B, et al. ACS Chem Neurosci. 2017 Jul 19;8(7):1448-1454. doi: 10.1021/acschemneuro.7b00027. Epub 2017 Apr 4. ACS Chem Neurosci. 2017. PMID: 28362078 - The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain.
Verleye M, Akwa Y, Liere P, Ladurelle N, Pianos A, Eychenne B, Schumacher M, Gillardin JM. Verleye M, et al. Pharmacol Biochem Behav. 2005 Dec;82(4):712-20. doi: 10.1016/j.pbb.2005.11.013. Epub 2006 Jan 4. Pharmacol Biochem Behav. 2005. PMID: 16388839 - The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis.
do Rego JL, Vaudry D, Vaudry H. do Rego JL, et al. PLoS One. 2015 Mar 18;10(3):e0120473. doi: 10.1371/journal.pone.0120473. eCollection 2015. PLoS One. 2015. PMID: 25785994 Free PMC article. - Axonal regeneration and neuroinflammation: roles for the translocator protein 18 kDa.
Girard C, Liu S, Adams D, Lacroix C, Sinéus M, Boucher C, Papadopoulos V, Rupprecht R, Schumacher M, Groyer G. Girard C, et al. J Neuroendocrinol. 2012 Jan;24(1):71-81. doi: 10.1111/j.1365-2826.2011.02215.x. J Neuroendocrinol. 2012. PMID: 21951109 Review. - Translocator protein as a promising target for novel anxiolytics.
Costa B, Da Pozzo E, Martini C. Costa B, et al. Curr Top Med Chem. 2012;12(4):270-85. doi: 10.2174/156802612799078720. Curr Top Med Chem. 2012. PMID: 22204481 Review.
Cited by
- The translocator protein 18kDa ligand etifoxine in the treatment of depressive disorders-a double-blind, randomized, placebo-controlled proof-of-concept study.
Brunner LM, Riebel M, Wein S, Koller M, Zeman F, Huppertz G, Emmer T, Eberhardt Y, Schwarzbach J, Rupprecht R, Nothdurfter C. Brunner LM, et al. Trials. 2024 Apr 22;25(1):274. doi: 10.1186/s13063-024-08120-x. Trials. 2024. PMID: 38650030 Free PMC article. Clinical Trial. - Translocator protein in the rise and fall of central nervous system neurons.
Cheung G, Lin YC, Papadopoulos V. Cheung G, et al. Front Cell Neurosci. 2023 Jun 21;17:1210205. doi: 10.3389/fncel.2023.1210205. eCollection 2023. Front Cell Neurosci. 2023. PMID: 37416505 Free PMC article. Review. - The Comprehensive Steroidome in Complete TSPO/PBR Knockout Mice under Basal Conditions.
Liere P, Liu GJ, Pianos A, Middleton RJ, Banati RB, Akwa Y. Liere P, et al. Int J Mol Sci. 2023 Jan 27;24(3):2474. doi: 10.3390/ijms24032474. Int J Mol Sci. 2023. PMID: 36768796 Free PMC article. - Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein.
Owen DR, Phillips A, O'Connor D, Grey G, Aimola L, Nicholas R, Matthews PM. Owen DR, et al. Br J Clin Pharmacol. 2022 Sep;88(9):4230-4236. doi: 10.1111/bcp.15392. Epub 2022 May 20. Br J Clin Pharmacol. 2022. PMID: 35524344 Free PMC article. - Mitochondrial Modulations, Autophagy Pathways Shifts in Viral Infections: Consequences of COVID-19.
Singh SP, Amar S, Gehlot P, Patra SK, Kanwar N, Kanwal A. Singh SP, et al. Int J Mol Sci. 2021 Jul 30;22(15):8180. doi: 10.3390/ijms22158180. Int J Mol Sci. 2021. PMID: 34360945 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources